citalopram has been researched along with Hemorrhage in 6 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the type of selective serotonin reuptake inhibitor used concurrently with rivaroxaban was not found to influence the patients' bleeding risk, a significant increase in the risk of bleeding was bserved based on the dose of rivaroxaban used." | 8.02 | Rivaroxaban and selective serotonin reuptake inhibitors: Bleeding risk resulting from their concomitant use. ( Bruni-Montero, MÁ; Canales-Siguero, D; Caro-Teller, JM; Ferrari-Piquero, JM; Hernández-Ramos, JA; Rosas-Espinoza, C, 2021) |
| "Although the type of selective serotonin reuptake inhibitor used concurrently with rivaroxaban was not found to influence the patients' bleeding risk, a significant increase in the risk of bleeding was bserved based on the dose of rivaroxaban used." | 4.02 | Rivaroxaban and selective serotonin reuptake inhibitors: Bleeding risk resulting from their concomitant use. ( Bruni-Montero, MÁ; Canales-Siguero, D; Caro-Teller, JM; Ferrari-Piquero, JM; Hernández-Ramos, JA; Rosas-Espinoza, C, 2021) |
| "To quantify the importance of drug-drug interactions (DDIs) in the occurrence of adverse drug reactions (ADRs) reported with serotoninergic reuptake inhibitors in a pharmacovigilance database." | 1.38 | The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. ( Bagheri, H; Bondon-Guitton, E; Bui, E; Durrieu, G; Lapeyre-Mestre, M; Montastruc, F; Montastruc, JL; Schmitt, L; Sommet, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bruni-Montero, MÁ | 1 |
| Caro-Teller, JM | 1 |
| Hernández-Ramos, JA | 1 |
| Rosas-Espinoza, C | 1 |
| Canales-Siguero, D | 1 |
| Ferrari-Piquero, JM | 1 |
| Sunitha, K | 1 |
| Hemshekhar, M | 1 |
| Gaonkar, SL | 1 |
| Sebastin Santhosh, M | 1 |
| Suresh Kumar, M | 1 |
| Priya, BS | 1 |
| Kemparaju, K | 1 |
| Rangappa, KS | 1 |
| Nanjunda Swamy, S | 1 |
| Girish, KS | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Montastruc, F | 1 |
| Sommet, A | 1 |
| Bondon-Guitton, E | 1 |
| Durrieu, G | 1 |
| Bui, E | 1 |
| Bagheri, H | 1 |
| Lapeyre-Mestre, M | 1 |
| Schmitt, L | 1 |
| Montastruc, JL | 1 |
| Al-Adwani, A | 1 |
| Kugelberg, FC | 1 |
| Alkass, K | 1 |
| Kingbäck, M | 1 |
| Carlsson, B | 1 |
| Druid, H | 1 |
6 other studies available for citalopram and Hemorrhage
| Article | Year |
|---|---|
Rivaroxaban and selective serotonin reuptake inhibitors: Bleeding risk resulting from their concomitant use.
Topics: Adolescent; Citalopram; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Selective Serotonin | 2021 |
Neutralization of haemorrhagic activity of viper venoms by 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-3-oxo-1,3-dihydroisobenzofuran-5-carbonitrile.
Topics: Animals; Benzofurans; Citalopram; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythrocytes; | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Antidepressive Agents; Citalopram; Conf | 2012 |
Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Resist | 2005 |
Influence of blood loss on the pharmacokinetics of citalopram.
Topics: Animals; Blood Chemical Analysis; Brain Chemistry; Chromatography, High Pressure Liquid; Citalopram; | 2006 |